Aprotinin (Synonyms: Bovine Pancreatic Trypsin Inhibitor, BPTI) |
| Katalog-Nr.GC12900 |
Ein Serinprotease-Inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 9087-70-1
Sample solution is provided at 25 µL, 10mM.
Aprotinin, a naturally occurring serine protease inhibitor, saves lives and decreases the risk of stroke and repeat surgery for massive bleeding1, 2, 3.
The use of aprotinin did not significantly increase the risk of renal failure or the need for postoperative renal replacement despite an increase in the proportion of patients who had a doubling of serum creatinine levels. The adjudication of death did not identify renal failure as contributing to or causing death associated with aprotinin use. A Meta analysis by Brown and colleagues showed a nonsignificant relative risk of renal failure with high-dose aprotinin4.
Although aprotinin is potentially more effective than other active agents in controlling hemostasis, we noted only a possible trend suggesting that it decreased massive bleeding. Only repeat surgeries and important blood losses through chest tubes, one of the main indications for surgery, were potentially improved by the use of aprotinin. Aprotinin did not appear to prevent massive bleeding or save the life of patients who had massive bleeding.
The adverse effects on mortality associated with aprotinin may also have been present among healthier patients, those under the age of 65 years, and those without coexisting illnesses at the time of surgery.
Despite the possibility of a modest reduction in the risk of massive bleeding, the strong and consistent negative mortality trend associated with aprotinin as compared with lysine analogues precludes its use in patients undergoing high-risk cardiac surgery5.
Reference:
1.Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007;4:CD001886.
2.Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet 1999;354:1940-7.
3.Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8.
4.Brown JR, Birkmeyer NJ, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801-13.
5.Dean A. Fergusson, Paul C. Hébert et al, A Comparison of Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery, N Engl J Med 2008; 358:2319-2331
| Cell experiment: [1] | |
|
Cell lines |
HUVEC cells |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while.Stock solution can be stored below -20°C for several months. |
|
Reaction Conditions |
1600 kIU/mL, 60 min |
|
Applications |
Aprotinin dose-dependently inhibited the TNF-α–induced expression of ICAM-1 and VCAM-1, but not E-selectin. |
| Animal experiment : [2] | |
|
Animal models |
3- to 4-mo-old male Albino Wistar rats |
|
Dosage form |
The rats were anesthetized by 50 mg/kg of ketamine initially and treated with 12 mmHg pneumoperitoneum for 4h. Additional lower doses of ketamine were administered i.p. until the end of pneumoperitoneum to maintain anesthesia. A loading aprotinin dose of 28000 KIU/kg was given i.p. after the onset of pneumoperitoneum, followed by lower maintenance doses (7500 KIU/kg), which were administered per hour until the termination. Splanchnic reperfusion period lasted 60 or 180 min. |
|
Applications |
Treatment of aprotinin caused reduction of several cytokines and markers (TNF-α, IL-6, endothelin 1, C reactive protein, PAB and carbonyl proteins) of oxidative stress in all tissues (liver, small intestine, and lung) studied. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Asimakopoulos G, Lidington E A, Mason J, et al. Effect of aprotinin on endothelial cell activation. The Journal of thoracic and cardiovascular surgery, 2001, 122(1): 123-128. [2] Baltatzis M, Pavlidis T E, Ouroumidis O, et al. Aprotinin reduces oxidative stress induced by pneumoperitoneum in rats. Journal of Surgical Research, 2014, 189(2): 238-248. |
|
| Cas No. | 9087-70-1 | SDF | |
| Überlieferungen | Bovine Pancreatic Trypsin Inhibitor, BPTI | ||
| Canonical SMILES | CC(O)=O.CC.CC.CCccC.[R].[P].[2H].[L].[E].[P].[P].[Y].[3H].[G].[KH].[R].[R].[Y].F.[Y].[*].[L].F.[V].[Y].[G].[G].[R].[KH].[R].N.N.F.[KH].S.[*].[2H].[R].[G].[G].[*].[KH].[*].[3H].C.[*].F.[P].[*].I.I.N.[Q].[3H].[M] | ||
| Formula | C284H432N84O79S7 | M.Wt | 6511.44 |
| Löslichkeit | ≥ 195mg/mL in Water | Storage | Store at 2-8°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 0.1536 mL | 0.7679 mL | 1.5358 mL |
| 5 mM | 0.0307 mL | 0.1536 mL | 0.3072 mL |
| 10 mM | 0.0154 mL | 0.0768 mL | 0.1536 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
-
Potency：6115U/mg (dried product)
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *